Інструкція із застосування TAD
Зміст інструкції
TAD 600 mg/4 ml powder and solvent for injectable solution, 2500 mg/25 ml powder and solvent for infusion solution
Glutathione
Read this leaflet carefully before you start to use this medicine as it contains important information for you.
- Keep this leaflet.
- You may need to read it again.
- If you have any questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only. Do not pass it on to others, even if their symptoms are the same as yours, as it may be harmful.
- If you get any side effects, even those not listed in this leaflet, tell your doctor or pharmacist. See section 4.
Contents of this leaflet:
- 1. What TAD is and what it is used for
- 2. What you need to know before you use TAD
- 3. How to use TAD
- 4. Possible side effects
- 5. How to store TAD
- 6. Contents of the pack and other information
1. What is TAD and what is it for?
TAD contains glutathione (GSH), a physiological tripeptide composed of glutamic acid,
cysteine and glycine which intervenes in numerous biological processes and plays an important
role in reactions for eliminating toxic substances from the body. Glutathione
administered parenterally belongs to the pharmacotherapeutic category of antidotes,
substances capable of transforming a toxic agent into a harmless or poorly damaging compound.
TAD is used for the prevention of neuropathy (disease of the nervous system)
resulting from treatment with drugs called chemotherapeutic agents, such as cisplatin or analogues, used
for the treatment of some types of cancer.
2. What you need to know before taking TAD
Do not take TAD
If you are allergic to glutathione or any of the other ingredients of this medicine.
Warnings and precautions
Talk to your doctor or nurse before using TAD .
Children and adolescents
The safety and efficacy of TAD in children have not been established.
Other medicines and TAD
Tell your doctor or pharmacist if you are taking, have recently taken, or might
take any other medicines.
At the recommended doses, TAD does not interfere with the therapeutic activity of the chemotherapeutic agent.
In the absence of incompatibility studies, the medicine should not be mixed with other products.
Pregnancy and breastfeeding
If you are pregnant, suspect you are pregnant, or are planning a pregnancy, or if you are breastfeeding
with breast milk, ask your doctor for advice before taking this medicine.
Available data indicate that glutathione, due to its nature as a substance physiologically present
in cells, does not cause undesirable effects in pregnant women or during
breastfeeding. Animal studies do not indicate direct or indirect harmful effects regarding
pregnancy, embryonic/fetal development, childbirth or postnatal development.
Driving and operating machinery
TAD does not alter, or alters negligibly, the ability to drive vehicles or operate
machinery.
3. How to take TAD
The generally recommended daily dose of TAD in patients undergoing chemotherapy
with cisplatin or analogues is 1.5 g/m (corresponding to 2.5 g) administered by slow
intravenous infusion.
However, the dosage depends on the patient's age, weight and clinical conditions and should
also be correlated with the dose and dosage schedule of the chemotherapeutic agent.
In case of glutathione administration in association with the chemotherapeutic agent, the
intravenous infusion of TAD should occur within 15-30 minutes before the start of
chemotherapy.
In the event of long-term therapies, lower doses of the product (600
mg) can be used, to be administered by intramuscular or slow intravenous infusion.
Method of administration
TAD “600 mg/4 ml powder and solvent for injectable solution”
Reconstitute the solution in the powder vial by drawing the water contained in the solvent vial
using a syringe with a suitable needle. Remove the aluminum tab on
the vial and disinfect the stopper with a cotton swab soaked in alcohol, then insert
the syringe needle into the vial through the center of the rubber stopper and direct the flow of
water towards the glass wall of the vial. Shake gently to promote complete
dissolution, then administer the resulting solution by intramuscular or
slow intravenous infusion.
TAD “2500 mg/25 ml powder and solvent for infusion solution”
First proceed to reconstitute the solution under aseptic conditions, operating with the
following methods:
- 1. Remove the aluminum tab from the powder vial and disinfect the stopper with a cotton swab soaked in alcohol
- 2. Remove only one cap from the disposable double-pointed perforator (transfer device) and insert the tip into the powder vial through the center of the rubber stopper
- 3. Remove the aluminum tab from the water vial and disinfect the rubber stopper, remove the second cap from the transfer device and insert the tip into the water vial, turning it upside down
- 4. Shake briefly to facilitate the flow of water into the powder vial, once the water vial is emptied, remove the transfer device and shake to promote dissolution
The administration of the reconstituted solution by intravenous infusion is then carried out in the
following way:
- 5. Disinfect the vial stopper again, then remove the cap of the perforator placed at the end of the infusion set and insert it into the center of the vial stopper;
- 6. Apply the tourniquet and tighten completely onto the tube;
- 7. Remove the cap of the needle holder and apply a needle;
- 8. Press the drip chamber to fill it about halfway, then open the tourniquet until all the air comes out of the set;
- 9. Close the tourniquet completely, insert the needle into a vein and slowly reopen the tourniquet until the desired flow rate is reached.
Important:Use immediately after opening the containers.
The reconstituted solution must be clear and free of visible particles. It is for single and
uninterrupted administration only and any residue cannot be used.
Use in children and adolescents
The safety and efficacy of TAD in children have not been established.
If you take more TAD than you should
No cases of overdose have been reported. If necessary, symptomatic treatments
can be used.
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Very rarely, skin rashes have been reported after intramuscular administration, which disappear upon stopping therapy. Pain at the injection site has also been reported.
As with all parenteral solutions, febrile reactions, infections at the injection site, venous thrombosis or phlebitis, and extravasation may occur.
In case of an immediate adverse reaction during intravenous infusion, stop the administration and, if possible, retain the unadministered fluid for possible examinations.
Reporting of side effects
If you experience any side effects, including those not listed in this leaflet, please inform your doctor, pharmacist, or nurse. You can also report side effects directly through the national reporting system at:
www.agenziafarmaco.gov.it/it/responsabili.
By reporting side effects you can help provide more information on the safety of this medicine.
5. How to store TAD
Keep this medicine out of the sight and reach of children
This medicine does not require any particular storage conditions.
Do not use this medicine after the expiry date that is reported on the label after Scad. The
expiry date refers to the last day of that month.
The reconstituted solution is stable for 8 hours at room temperature.
Do not use this medicine if you notice the presence of particles, an abnormal coloration,
turbidity or precipitate.
Do not dispose of any medicine in wastewater or household waste. Ask your pharmacist
how to eliminate medicines that you no longer use. This will help protect the environment.
6. Package contents and other information
What TAD contains
TAD 600 mg/4 ml powder and solvent for injectable solution
- The active ingredient is sodium glutathione 646 mg equivalent to glutathione 600 mg
- The other component is water for injections. The reconstituted solution contains 150 mg/ml of glutathione.
TAD 2500 mg/25 ml powder and solvent for infusion solution
- The active ingredient is sodium glutathione 2680 mg equivalent to glutathione 2500 mg
- The other component is water for injections. The reconstituted solution contains 100 mg/ml of glutathione.
The powder vials contain only the active ingredient and the solvent vials or solvent ampoules contain water for injections.
Description of the appearance of TAD and package contents
TAD 600 mg/4 ml powder and solvent for injectable solution
The pack contains 5 vials of powder of 600 mg and 5 ampoules of solvent of 4 ml.
The pack contains 10 vials of powder of 600 mg and 10 ampoules of solvent of 4 ml.
TAD 2500 mg/25 ml powder and solvent for infusion solution
The pack contains 1 vial of powder of 2500 mg and 1 vial of solvent of 25 ml.
The package also contains an intravenous infusion set for the extemporaneous preparation of the solution.
Marketing authorization holder
BIOMEDICA FOSCAMA INDUSTRIA CHIMICO-FARMACEUTICA S.p.A.
Via dei Castelli Romani, 22
00071 Pomezia (RM) Italy
Manufacturer
BIOMEDICA FOSCAMA INDUSTRIA CHIMICO-FARMACEUTICA S.p.A.
Plant: Via Morolense, 87
03013 Ferentino (FR) – (Italy)

- Країна реєстрації
- Лікарська формаPowder and solvent for injectable solution, 600 MG/4 ML
- Код АТХV03AB32
- Діюча речовина
- Потрібен рецептТак
- Виробник
- Ця інформація надана лише для ознайомлення і не є медичною порадою. Рішення щодо лікування завжди приймає лікар.
- Альтернативи до TADЛікарська форма: Powder and solvent for injectable solution, 300 MG/3 MLДіюча речовина: ГлутатионВиробник: LABORATORIO FARMACEUTICO C.T. S.R.L.Потрібен рецептЛікарська форма: Powder and solvent for injectable solution, 600 MG/4 MLДіюча речовина: ГлутатионВиробник: ESSETI FARMACEUTICI S.R.L.Потрібен рецептЛікарська форма: Powder and solvent for injectable solution, 600 MG/4 MLДіюча речовина: ГлутатионПотрібен рецепт
Аналоги TAD в інших країнах
Препарати з тією самою діючою речовиною, доступні в інших країнах.
Аналог TAD у Україна
Аналог TAD у Польща
Аналог TAD у Іспанія
Лікарі онлайн щодо TAD
Застосування, безпека та можливість призначення рецепта — за результатами медичної оцінки.
Отримайте рецепт на TAD онлайн
Заповніть форму за 2 хвилини
Розкажіть про симптоми, історію хвороби та потрібний препарат.
Оберіть лікаря або ми призначимо
Оберіть спеціаліста або ми підберемо найближчого доступного лікаря.
Лікар розглядає ваш випадок
Зазвичай протягом 30 хвилин. Може ставити уточнювальні запитання в чаті.
Отримайте в будь-якій аптеці
Електронний рецепт надсилається на вашу пошту — дійсний по всій Польщі.
Часті запитання
TAD потребує рецепта в Італія. Ви можете обговорити з лікарем онлайн, чи підходить цей лікарський засіб для вашої ситуації.
Діюча речовина у TAD — Глутатион. Це допомагає визначити препарати з тим самим складом, але під іншими торговими назвами.
TAD виробляється компанією BIOMEDICA FOSCAMA INDUSTRIA CHIMICO-FARMACEUTICA S.P.A.. Назва бренду та упаковка можуть відрізнятися залежно від дистрибʼютора.
Лікарі, зокрема Сімейні лікарі, Психіатри, Дерматологи, Кардіологи, Ендокринологи, Гастроентерологи, Пульмонологи, Нефрологи, Ревматологи, Гематологи, Інфекціоністи, Алергологи, Геріатри, Педіатри, Онкологи, можуть оцінити доцільність застосування TAD з урахуванням вашого стану та місцевих правил. Ви можете записатися на онлайн-консультацію, щоб обговорити симптоми та можливі подальші кроки.
Польща має добре розвинену систему охорони здоров'я у великих містах, таких як Варшава, Краків, Вроцлав і Гданськ. Аптеки широко доступні та працюють відповідно до чинного законодавства, забезпечуючи доступ до рецептурних препаратів.
Ви можете придбати TAD у Варшаві, Кракові, Вроцлаві або Гданську в будь-якій аптеці за наявності дійсного рецепта.
Щоб отримати рецепт, ви можете скористатися Oladoctor:
Інші препарати з тією самою діючою речовиною (Глутатион) включають LUTION, YDROXIA, RIDUTOX. Вони можуть відрізнятися торговою назвою або формою випуску, але містять той самий терапевтичний компонент. Перед зміною або початком прийому нового препарату варто проконсультуватися з лікарем.
















